Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

NCT06930352 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Cytarabine
PROCEDURE: Echocardiography Test
DRUG: Hydroxyurea
PROCEDURE: Leukapheresis
PROCEDURE: Multigated Acquisition Scan
OTHER: Questionnaire Administration
DRUG: Ziftomenib

Sponsor

Uma Borate

Collaborators

[object Object]